Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
Year: 2001
Type: article
Study design: Clinical Trial
Source: PubMed
Institution: National Cancer Center Hospital East
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1831172932
